Gilead's experimental HIV treatment non-inferior to blockbuster drug in trial

Gilead Sciences said on Monday its experimental HIV treatment was found to be statistically non-inferior to its top-selling ...

Gilead’s experimental HIV treatment meets main goal in late-stage trial

Gilead Sciences said on Monday its experimental HIV treatment met the main goal and was found to be statistically ...

BME: Monthly Income With Upside From The Out-Of-Favor Healthcare Sector

BlackRock Health Sciences Trust is a Buy for income investors, offering an 8% yield, NAV discount, and resilient healthcare ...

Gilead Sciences Inc. stock underperforms Wednesday when compared to competitors despite daily gains

The stock's rise snapped a four-day losing streak.
Fierce Pharma

Gilead's single-tablet HIV combo of bictegravir, lenacapavir passes another late-stage test on way to filings

With a second late-stage trial win for its investigational HIV combo in the books, Gilead Sciences is moving full steam ahead ...
Zacks.com on MSN

GILD's Bictegravir and Lenacapavir Regimen for HIV Meets Primary Goal

Gilead said its once-daily bictegravir/lenacapavir tablet met non-inferiority vs Biktarvy in phase III ARTISTRY-2, paving the way for filings.

Gilead’s Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-2 Trial

Gilead Sciences, Inc. (Nasdaq: GILD) today announced positive topline results from the Phase 3 ARTISTRY-2 trial. The ...

Gilead's Experimental Combo Tablet For HIV Treatment Hits Primary Goal

Gilead said its two-drug bictegravir-lenacapavir tablet was non-inferior to Biktarvy in the Phase 3 ARTISTRY-2 HIV trial.

Gilead to start demolishing buildings for campus expansion by end of month

Choose San Francisco Business Times as a preferred news source to see more of our reporting on Google. It is the first work ...

Gilead Sciences' HIV Treatment Meets Primary Endpoint in Late-Stage Trial

Gilead Sciences said its in-development HIV treatment met the primary endpoint of a recent late-stage clinical trial. The biopharmaceutical company said Monday that the treatment, a once-daily single ...

Gilead Sciences Inc. stock underperforms Thursday when compared to competitors despite daily gains

This was the stock's second consecutive day of gains.

Here's What We Like About Gilead Sciences' (NASDAQ:GILD) Upcoming Dividend

Gilead Sciences, Inc. (NASDAQ:GILD) stock is about to trade ex-dividend in 4 days. The ex-dividend date is one business day ...